Project Grant HT94252410087
Award Date
5/1/24
Completion Date
4/30/27
Dollars Obligated
$842K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
The University of Cambridge received a $1,996,828.00 four-year Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research to develop predictive models for treatment response, early relapse, and survival in breast cancer across molecular subtypes. The University will leverage multi-modal data integration techniques to explore early signals of later metastatic recurrence. This research aims to...
The University of Cambridge received a $4,598,677 Project Grant from the Defense Health Agency to conduct research under the Military Medical Research and Development program (CFDA 12.420). The research aims to use multi-modal data integration across breast cancer molecular subtypes to develop predictors of treatment response, early relapse, and survival, as well as explore early signals of later metastatic recurrence. The 4-year grant, which began on September 1, 2023, leverages the...
The University of Cambridge received a $824,548 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the role of hypoxia in vasculogenic mimicry, response to therapy, and metastasis. This 3-year grant awarded on May 1, 2024 will support basic, translational, and clinical research to advance scientific understanding and develop new treatments in areas such as cancer, neurological...
The University of Cambridge will receive $439,922 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research from September 2022 through September 2025 to dissect ovarian cancer tumor-immune microenvironments through 3D in situ molecular profiling. The Military Medical Research and Development program aims to transform military and public health through innovative medical research...
This Project Grant from the Defense Health Agency provides $494,811 to the University of Cambridge under the Military Medical Research and Development program (CFDA 12.420) from April 1, 2023 to March 31, 2026. The grant funds research to elucidate and target clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
This Project Grant award from the Defense Health Agency provides $377,681 to the University of Cambridge for research elucidating and targeting clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The award period runs from April 1, 2023 through March 31, 2026. The research funded under this award directly supports the Military Medical Research and Development program's goal of investigating medical solutions for the...
The U.S. Air Force awarded a $134,234 Project Grant to the University of Cambridge in the United Kingdom under the Air Force Defense Research Sciences Program (CFDA 12.800). The grant, with a performance period from December 1, 2024 to November 30, 2027, will fund research to develop "functional probes for psychiobiotic monitoring". This research aims to maintain technological superiority and create strategic advantages for the U.S. Air Force and Space Force in areas critical to...
The U.S. Defense Health Agency awarded King's College London a $1,712,517 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to identify molecular predictors of risk and validate the evolution of ductal carcinoma in situ (DCIS) over a 4-year period ending on September 29, 2027. As the prime awardee, King's College London will leverage its expertise in biomedical research to advance the scientific understanding of breast cancer progression. This award supports...
The University of Massachusetts Amherst was awarded a $557,247 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from February 1, 2023 to January 31, 2026 to develop intracellular bacterial delivery of vaccine antigens to establish T-cell antitumor immunity in triple-negative breast cancer. The Military Medical Research and Development program supports innovative medical research with...
This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...